[go: up one dir, main page]

BRPI0516602A - composto, e, composição farmacêutica - Google Patents

composto, e, composição farmacêutica

Info

Publication number
BRPI0516602A
BRPI0516602A BRPI0516602-0A BRPI0516602A BRPI0516602A BR PI0516602 A BRPI0516602 A BR PI0516602A BR PI0516602 A BRPI0516602 A BR PI0516602A BR PI0516602 A BRPI0516602 A BR PI0516602A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
migraine
schizophrenia
depression
Prior art date
Application number
BRPI0516602-0A
Other languages
English (en)
Inventor
Thomas Charles Britton
Veronique Dehlinger
Colin Peter Dell
Bruce Anthony Dressman
Jason Kenneth Myers
Eric Samuel Nisenbaum
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0516602A publication Critical patent/BRPI0516602A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

COMPOSTO, E, COMPOSIçãO FARMACêUTICA. A presente invenção refere-se a compostos da Fórmula (1) que são úteis para tratar condições associadas com receptores mGluR~ 3~, como depressão, esquizofrenia, e enxaqueca, composições farmacêuticas dos mesmos, e métodos de uso dos mesmos.
BRPI0516602-0A 2004-10-18 2005-10-13 composto, e, composição farmacêutica BRPI0516602A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61978904P 2004-10-18 2004-10-18
PCT/US2005/036665 WO2006044454A1 (en) 2004-10-18 2005-10-13 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0516602A true BRPI0516602A (pt) 2008-09-16

Family

ID=35787981

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516602-0A BRPI0516602A (pt) 2004-10-18 2005-10-13 composto, e, composição farmacêutica

Country Status (12)

Country Link
US (1) US7868014B2 (pt)
EP (1) EP1805165B1 (pt)
JP (1) JP5188807B2 (pt)
CN (1) CN101094846A (pt)
AT (1) ATE452130T1 (pt)
AU (1) AU2005295860A1 (pt)
BR (1) BRPI0516602A (pt)
CA (1) CA2584422A1 (pt)
DE (1) DE602005018381D1 (pt)
ES (1) ES2336130T3 (pt)
MX (1) MX2007004661A (pt)
WO (1) WO2006044454A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028373T2 (en) 2004-05-28 2017-02-28 Mitsubishi Tanabe Pharma Corp Arylalkylamines and processes for their preparation
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
EP2145891A1 (en) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
TW201022233A (en) * 2008-11-04 2010-06-16 Organon Nv (Pyrrolidin-2-yl)phenyl derivatives
HK1215170A1 (zh) 2012-11-14 2016-08-19 The Johns Hopkins University 治療精神分裂症的方法和組合物
WO2016092002A1 (en) * 2014-12-11 2016-06-16 Janssen Pharmaceutica Nv 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of mglur2 receptors
CN113024412A (zh) * 2021-03-23 2021-06-25 上海立科化学科技有限公司 2,4,6-三氯苯腈的制备方法
CN114149297A (zh) * 2021-12-07 2022-03-08 北京中医药大学 一种微波辅助的选择性芳基甲醛的绿色合成方法
CN115368283A (zh) * 2022-09-15 2022-11-22 丽水绿氟科技有限公司 一种手性结构或非手性结构的顺式-3-氟-4-羟基吡咯烷及其衍生物的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4785119A (en) 1985-10-11 1988-11-15 Tokyo Kasei Kogyo Co., Ltd. 3-aminopyrrolidine compound and process for preparation thereof
US5332817A (en) 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
WO1991009844A1 (en) 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
TW202432B (pt) 1991-06-21 1993-03-21 Pfizer
US5686482A (en) * 1994-04-28 1997-11-11 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl) benzamide derivative
ES2079323B1 (es) * 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1997026300A1 (en) 1996-01-22 1997-07-24 Eli Lilly And Company Combinatorial process for preparing substituted indane libraries
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
US5891889A (en) * 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1000015A1 (en) 1997-07-18 2000-05-17 Georgetown University Bicyclic metabotropic glutamate receptor ligands
WO1999004778A1 (en) 1997-07-22 1999-02-04 Eli Lilly And Company Pharmaceutical compounds
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
WO1999064396A1 (en) * 1998-06-09 1999-12-16 Neurogen Corporation Substituted 1-aryl-3-benzylaminopyrrolidine: dopamine receptor subtype specific ligands
CA2446605A1 (en) * 2001-05-10 2002-11-21 Aventis Pharma Deutschland Gmbh Novel processes for the preparation of adenosine compounds and intermediates thereto
AU2003300021A1 (en) * 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2004247487B2 (en) 2003-06-17 2010-05-20 Pfizer Inc. N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
US8163753B2 (en) 2003-10-31 2012-04-24 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
HUE028373T2 (en) * 2004-05-28 2017-02-28 Mitsubishi Tanabe Pharma Corp Arylalkylamines and processes for their preparation

Also Published As

Publication number Publication date
ATE452130T1 (de) 2010-01-15
EP1805165A1 (en) 2007-07-11
CA2584422A1 (en) 2006-04-27
US20080300266A1 (en) 2008-12-04
CN101094846A (zh) 2007-12-26
WO2006044454A1 (en) 2006-04-27
ES2336130T3 (es) 2010-04-08
JP5188807B2 (ja) 2013-04-24
DE602005018381D1 (de) 2010-01-28
EP1805165B1 (en) 2009-12-16
AU2005295860A1 (en) 2006-04-27
JP2008516959A (ja) 2008-05-22
US7868014B2 (en) 2011-01-11
MX2007004661A (es) 2007-06-22

Similar Documents

Publication Publication Date Title
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
SG163585A1 (en) Melanocortin receptor ligands
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
ATE537170T1 (de) Cgrp-rezeptorantagonisten
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MY153915A (en) Organic compounds
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
NO20072435L (no) CGRP-reseptorantagonister
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
WO2008156677A3 (en) Cyclic peptide melanocortin receptor ligands
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
EA200800321A1 (ru) Ингибиторы гистондеацетилазы
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
SE0303180D0 (sv) Novel compounds
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
SE0302232D0 (sv) Novel Compounds
MA32508B1 (fr) Composes organiques
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
ATE503755T1 (de) Cgrp-rezeptorantagonisten
BRPI0516602A (pt) composto, e, composição farmacêutica
EA200800540A1 (ru) Карбоксамидные производные в качестве антагонистов мускариновых рецепторов

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.